| UNITED STATES | |
| SECURITIES AND EXCHANGE COMMISSION | |
| Washington, D.C. 20549 | |
| Notice of Effectiveness | |
| Effectiveness Date: | May 15, 2025 4:00 P.M. |
| Form: | S-3 | ||||||
| |||||||
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 10/20/2021 | $14.00 | Buy | Truist Securities |
| 9/24/2021 | $7.00 | Overweight | Cantor Fitzgerald |
DENVER, Jan. 06, 2026 (GLOBE NEWSWIRE) -- Markets are opening with a clear appetite for substance over speculation, as investors gravitate toward companies delivering late-stage clinical wins, scalable science, and data-driven precision platforms. Alumis (NASDAQ:ALMS): Phase 3 Data Redefines the Oral Psoriasis Landscape Alumis is firmly in focus after announcing positive topline results from two Phase 3 trials (ONWARD1 and ONWARD2) evaluating envudeucitinib, its next-generation oral TYK2 inhibitor, in moderate-to-severe plaque psoriasis. Both trials met all primary and secondary endpoints with high statistical significance, with efficacy that stands out among oral therapies. By Week 24,
– Cyclerion Strengthens Development of Closed-Loop Anesthetic Platform through Strategic Collaboration Agreement with Medsteer – – Comprehensive Business Update and Path to Initiating Phase 2 Proof-of-Concept ("POC") Study in the Second Half of 2026 – – Webcast Being Held on January 6, 2026 at 8:00 a.m. ET, Featuring Key Opinion Leader, Dr. Husseini Manji – CAMBRIDGE, Mass., Jan. 05, 2026 (GLOBE NEWSWIRE) -- Cyclerion Therapeutics, Inc. (NASDAQ:CYCN), a biopharmaceutical company pioneering neuropsychiatric therapies, today announced an application-specific, exclusive collaboration with Medsteer, a leader in anesthetic delivery systems driven by real-time patient feedback. The new collab
– Cyclerion Relaunches, Advancing a Phase 2–Ready Program for Millions Living with Treatment-Resistant Depression Through MIT License Agreement – – Webcast to be held September 24, 2025 at 10:30 a.m. ET – CAMBRIDGE, Mass., Sept. 23, 2025 (GLOBE NEWSWIRE) -- Cyclerion Therapeutics, Inc. today announced that it has entered into a licensing agreement with the Massachusetts Institute of Technology ("MIT"), securing the intellectual property that will serve as the cornerstone of its strategic relaunch. This agreement marks a pivotal milestone in Cyclerion's transformation into a new, innovation-driven company focused on delivering potential novel, improved or first--in-class therapies for neu
8-K - Cyclerion Therapeutics, Inc. (0001755237) (Filer)
8-K - Cyclerion Therapeutics, Inc. (0001755237) (Filer)
10-Q - Cyclerion Therapeutics, Inc. (0001755237) (Filer)
Truist Securities initiated coverage of Cyclerion Therapeutics with a rating of Buy and set a new price target of $14.00
Cantor Fitzgerald initiated coverage of Cyclerion Therapeutics with a rating of Overweight and set a new price target of $7.00
4 - Cyclerion Therapeutics, Inc. (0001755237) (Issuer)
4 - Cyclerion Therapeutics, Inc. (0001755237) (Issuer)
4 - Cyclerion Therapeutics, Inc. (0001755237) (Issuer)
– Dr. Graul will lead the rebuild of Cyclerion, bringing more than two decades of drug making experience, R&D portfolio leadership, and a deep expertise in company strategy – – Peter Hecht, Ph.D., will continue to work closely with Cyclerion leadership as a strategic consultant and longstanding board member; steps down from CEO role – CAMBRIDGE, Mass., Dec. 04, 2023 (GLOBE NEWSWIRE) -- Cyclerion Therapeutics, Inc. (NASDAQ:CYCN), a biopharmaceutical company on a mission to develop treatments for serious diseases, today announced that Regina Graul, Ph.D., has joined the company as president, effective immediately. As Cyclerion's president, she will lead the organization and will work close
Positive topline results for CY6463 announced in two clinical studies in patients with Mitochondrial Encephalomyopathy, Lactic Acidosis and Stroke-like episodes (MELAS) and Cognitive Impairment Associated with Schizophrenia (CIAS) Study in Alzheimer's Disease with vascular pathology (ADv) enrollment ongoing Appointed Steven E. Hyman, M.D. to its Board of Directors CAMBRIDGE, Mass., Aug. 09, 2022 (GLOBE NEWSWIRE) -- Cyclerion Therapeutics, Inc. (NASDAQ:CYCN), a clinical-stage biopharmaceutical company on a mission to develop treatments that restore cognitive function, today announced second quarter 2022 financial results and a business update. "The data generated from our recent
CAMBRIDGE, Mass., July 26, 2022 (GLOBE NEWSWIRE) -- Cyclerion Therapeutics, Inc. (NASDAQ:CYCN), a clinical-stage biopharmaceutical company on a mission to develop treatments that restore cognitive function, today announced the appointment of Steven E. Hyman, M.D., to its Board of Directors effective July 25. Dr. Hyman will work with Cyclerion leadership to help shape the future of its research and clinical development strategy while expanding external collaborations with scientific leaders and industry partners. "We are delighted to welcome Dr. Steve Hyman to Cyclerion. Steve is a world-renowned leader in neuroscience with deep expertise leading large-scale, collaborative research program
SC 13G/A - Cyclerion Therapeutics, Inc. (0001755237) (Subject)
SC 13G/A - Cyclerion Therapeutics, Inc. (0001755237) (Subject)
SC 13G/A - Cyclerion Therapeutics, Inc. (0001755237) (Subject)